Genmab and Incyte Launch Colorectal Cancer Trial
The companies are testing a new combination drug therapy for patients with specific KRAS G12D-mutated metastatic colorectal cancer.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes when researching new combination cancer therapies?
Genmab and Incyte have initiated a clinical trial collaboration to evaluate a first-line treatment for patients with KRAS G12D-mutated metastatic colorectal cancer. The study will test the combination of petosemtamab and INCB161734 alongside standard-of-care chemotherapy.
Why it matters
The collaboration seeks to address a significant unmet medical need for patients with this specific mutation. By combining agents with complementary mechanisms, the study aims to establish a new first-line treatment option.
KRAS mutations are present in approximately 40% of all colorectal cancer cases. The G12D mutation is the most frequent among these genetic markers, also appearing in 40% of pancreatic ductal adenocarcinoma cases.
The players
Genmab
Headquartered in Copenhagen, Denmark, this biotechnology company focuses on developing antibody-based therapeutics for cancer treatment.
Incyte
Based in Wilmington, Delaware, this biopharmaceutical company specializes in discovering and developing therapies for oncology and inflammation.
The details
Genmab will conduct the Phase 1/2 study, while Incyte provides the necessary clinical supply of INCB161734. The research evaluates whether combining KRAS G12D inhibition with LGR5-targeted EGFR inhibition and chemotherapy improves outcomes.
Timeline
October 24, 2026: Genmab and Incyte announced their clinical trial collaboration.
The Big Picture
This research adds to the comprehensive catalog of experimental medical studies currently tracked by the clinical trial information portal. The collaboration reflects an industry-wide shift toward targeting specific genetic mutations in complex cancer cases.
This trial aims to develop a new treatment pathway that could eventually expand options for patients with difficult-to-treat colorectal cancer. While currently in early-phase testing, the study represents a potential future shift in first-line therapy standards.
The takeaway
This collaboration highlights the growing importance of targeting specific genetic mutations in advanced cancer treatment. Patients and families are encouraged to consult their oncologists regarding the potential for clinical trial participation.
Further reading
For more information on ongoing oncological research, visit the Cancer section.
More information
Find active research study listings on the clinical trial information portal.
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes when researching new combination cancer therapies?
